Management of Intermediate-Risk Pulmonary Embolism with Renal Impairment and Cancer

Initial Anticoagulation Strategy

The European Society of Cardiology recommends starting unfractionated heparin (UFH) with a weight-adjusted bolus immediately for patients with intermediate-risk pulmonary embolism and severe renal impairment, without waiting for complete diagnostic confirmation 1, 2, 3
Target aPTT range of 1.5-2.5 times normal with UFH infusion, as recommended by the European Heart Journal 4
The European Society of Cardiology advises against using direct oral anticoagulants (DOACs) in patients with severe renal impairment, as they are contraindicated 1, 2, 3
The European Society of Cardiology also recommends against using low molecular weight heparin (LMWH) or fondaparinux for initial therapy if creatinine clearance is severely impaired, due to increased bleeding risk 1, 2

The European Society of Cardiology recommends against routine primary thrombolysis for intermediate-risk pulmonary embolism, even with RV dysfunction or elevated biomarkers, due to increased bleeding risk 1, 2, 3, 5
Reserve thrombolysis only for rescue therapy if the patient develops hemodynamic deterioration despite adequate anticoagulation, as recommended by the European Society of Cardiology 1, 2, 3, 5

Close monitoring is essential to identify patients who require escalation to rescue therapy, according to the European Society of Cardiology 5
Monitor for signs of hemodynamic compromise, such as persistent hypotension, new vasopressor requirement, worsening hypoxemia, altered mental status, or rising lactate, as recommended by the European Society of Cardiology 1, 2
Serial assessment of RV function by echocardiography and cardiac biomarkers helps identify deterioration, according to the European Society of Cardiology 5

Avoid aggressive fluid boluses, as they worsen RV failure by increasing RV afterload, according to the European Heart Journal 4, 1
Use vasopressors, such as norepinephrine and/or dobutamine, if hypotension develops, as recommended by the European Society of Cardiology 1, 2, 3
Administer supplemental oxygen for hypoxemia, as recommended by the Praxis Medical Insights 5

Once stabilized on UFH and renal function is clarified, transition to LMWH for long-term therapy if creatinine clearance permits, as recommended by the European Heart Journal 4
LMWH is superior to warfarin in cancer-associated thrombosis, and at least 6 months of LMWH is recommended, followed by continued LMWH or VKA as long as cancer is active, according to the European Heart Journal 4

Define "impaired renal function" precisely by measuring creatinine clearance to determine if severe or moderate, as recommended by the European Society of Cardiology 1, 2
If creatinine clearance is 30-50 mL/min, dose-adjusted LMWH may be considered after initial UFH stabilization, but requires careful monitoring, according to the European Society of Cardiology 1, 2

Consider activating a Pulmonary Embolism Response Team (PERT) for complex patients with multiple comorbidities, such as cancer, renal impairment, and intermediate-risk pulmonary embolism, as recommended by the European Society of Cardiology 3, 5
PERT can facilitate real-time decision-making regarding anticoagulation adjustments, monitoring intensity, and potential need for advanced interventions, according to the European Society of Cardiology 3